Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?
about
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxisHaemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demandNHF-McMaster Guideline on Care Models for Haemophilia Management.Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sUse of quality checklists and need for disease-specific guidance in economic evaluations: a meta-review.Making economic evaluations more helpful for treatment choices in haemophilia.Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidence.Social/economic costs and quality of life in patients with haemophilia in Europe.Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.Health economic models in hemophilia A and utility assumptions from a clinician's perspective.The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.The association of haemophilic arthropathy with Health-Related Quality of Life: a post hoc analysis.Assessing options for treating haemophilia with inhibitors.Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions.National needs assessment of patients treated at the United States Federally-Funded Hemophilia Treatment Centers.An innovative outcome-based care and procurement model of hemophilia management.Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress. Understanding health outcomes: focus on haemophilia.
P2860
Q26865814-EE7E8EE4-32E9-4867-B6C5-12A281EFE95BQ28082558-F4042C17-1B9F-4E75-B6AA-E631A60A9902Q30249305-6E5C986D-432F-42C8-A859-04D38EDDB3DCQ37098836-DE16AFDE-F3F1-44A2-87A1-8B64C8412FFFQ38547506-C2128343-1E36-429F-BC2C-1A87CF2993EEQ38767186-62327D84-E65A-4FD9-9404-0B4FDFC483FBQ38783210-56CF9AEA-26C2-417D-81D7-18BD91064C2BQ38885402-FB260815-8596-4DC3-9AF6-FDF243B4F427Q39252827-1437A26C-3AE7-4449-AFA6-0BF11BC91DA8Q40938357-B3CF706C-2543-4BE4-BDA7-1EEE7A1FF408Q44576554-3CF1C074-09B1-4E22-BFD9-112A537B6170Q45861291-45F2D153-C3EC-42FB-AAD9-89EAE24C0F05Q45874793-9EB9A0D5-49B1-4EFE-8122-632A99D92969Q45874959-582AC074-C000-453C-A7BD-E040ED86A338Q45880326-7D0912A8-AA3A-4DC6-A257-92310754D7CBQ45884983-3203CB36-8394-4B28-8A65-7BE86ECB556DQ45886106-ED0B0168-0224-4ED7-A38D-E6A32BAD5827Q45886531-4AE0B044-3607-412C-8A0D-C5634AE88478
P2860
Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Economic evaluations of prophy ...... y do the results vary so much?
@en
type
label
Economic evaluations of prophy ...... y do the results vary so much?
@en
prefLabel
Economic evaluations of prophy ...... y do the results vary so much?
@en
P2860
P356
P1433
P1476
Economic evaluations of prophy ...... y do the results vary so much?
@en
P2093
A H Miners
P2860
P304
P356
10.1111/HAE.12009
P577
2012-09-19T00:00:00Z